Literature DB >> 8380472

Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.

S M Lang1, M Weeger, C Stahl-Hennig, C Coulibaly, G Hunsmann, J Müller, H Müller-Hermelink, D Fuchs, H Wachter, M M Daniel.   

Abstract

The importance of the vpr gene for simian immunodeficiency virus (SIV) replication, persistence, and disease progression was examined by using the infectious pathogenic molecular clone called SIVmac239. The ATG start codon of the vpr gene was converted to TTG by site-specific mutagenesis. The constructed Vpr- mutant virus is identical with the parental SIVmac239/nef-stop virus with the exception of this one nucleotide. These viruses replicated with similar kinetics and to similar extents in rhesus monkey lymphocyte cultures and in the human CEMX174 cell line. Five rhesus monkeys were inoculated with the Vpr- variant of SIVmac239/nef-stop, and two monkeys received SIVmac239/nef-stop as controls. Both controls showed reversion of the TAA stop signal in nef by 2 weeks postinfection, as has been observed previously. Reversion of the TAA stop codon in nef also occurred in the five monkeys that received the Vpr- variant, but reversion was delayed on average to about 4 weeks. Thus, the mutation in vpr appeared to delay the rapidity with which reversion occurred in the nef gene. Reversion of the TTG sequence in vpr to ATG was observed in three of the five test animals. Reversion in vpr was first observed in these three animals 4 to 8 weeks postinfection. No vpr revertants were found over the entire 66 weeks of observation in the other two test animals that received the vpr mutant. Antibodies to vpr developed in those three animals in which reversion of vpr was documented, but antibodies to vpr were not observed in the two animals in which reversion of vpr was not detected. Antibody responses to gag and to whole virus antigens were of similar strength in all seven animals. Both control animals and two of the test animals in which vpr reverted maintained high virus loads and developed progressive disease. Low virus burden and no disease have been observed in the two animals in which vpr did not revert and in the one animal in which vpr reversion was first detected only at 8 weeks. The reversion of vpr in three of the five test animals indicates that there is significant selective pressure for functional forms of vpr in vivo. Furthermore, the results suggest that both vpr and nef are important for maximal SIV replication and persistence in vivo and for disease progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380472      PMCID: PMC237444     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates.

Authors:  D Fuchs; J Albert; B Asjö; E M Fenyö; G Reibnegger; H Wachter
Journal:  J Infect Dis       Date:  1989-10       Impact factor: 5.226

3.  Efficient DNA transfection and rapid assay for thymidine kinase activity and viral antigenic determinants.

Authors:  G Milman; M Herzberg
Journal:  Somatic Cell Genet       Date:  1981-03

4.  The nucleotide sequence of the human beta-globin gene.

Authors:  R M Lawn; A Efstratiadis; C O'Connell; T Maniatis
Journal:  Cell       Date:  1980-10       Impact factor: 41.582

5.  Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals.

Authors:  P Reiss; J M Lange; A de Ronde; F de Wolf; J Dekker; S A Danner; C Debouck; J Goudsmit
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 6.  Use of simian immunodeficiency viruses for AIDS research.

Authors:  R C Desrosiers; D J Ringler
Journal:  Intervirology       Date:  1989       Impact factor: 1.763

7.  Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection.

Authors:  C Stahl-Hennig; G Voss; S Nick; H Petry; D Fuchs; H Wachter; C Coulibaly; W Lüke; G Hunsmann
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

8.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14.

Authors:  S Dewhurst; J E Embretson; D C Anderson; J I Mullins; P N Fultz
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

9.  Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor.

Authors:  S R Hammes; E P Dixon; M H Malim; B R Cullen; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Sequence of a novel simian immunodeficiency virus from a wild-caught African mandrill.

Authors:  H Tsujimoto; A Hasegawa; N Maki; M Fukasawa; T Miura; S Speidel; R W Cooper; E N Moriyama; T Gojobori; M Hayami
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

View more
  107 in total

1.  The first HxRxG motif in simian immunodeficiency virus mac239 Vpr is crucial for G(2)/M cell cycle arrest.

Authors:  Sandra M Mueller; Sabine M Lang
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies.

Authors:  F Li; C Leroux; J K Craigo; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Regulatory genes of simian immunodeficiency viruses from west African green monkeys (Cercopithecus aethiops sabaeus).

Authors:  V Jubier-Maurin; P Sarni-Manchado; F Veas; N Vidal; F Bibollet-Ruche; J P Durand; A Galat-Luong; G Cuny
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Authors:  Bärbel Schröfelbauer; Qin Yu; Samantha G Zeitlin; Nathaniel R Landau
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R.

Authors:  Sergey Iordanskiy; Yuqi Zhao; Larisa Dubrovsky; Tatiana Iordanskaya; Mongzhong Chen; Dong Liang; Michael Bukrinsky
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.